Back to Search
Start Over
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies
- Source :
- Biomark Med
- Publication Year :
- 2021
- Publisher :
- Future Medicine Ltd, 2021.
-
Abstract
- Gastrointestinal cancers encompass a diverse class of tumors arising in the GI tract, including esophagus, stomach, pancreas and colorectum. Collectively, gastrointestinal cancers compose a high fraction of all cancer deaths, highlighting an unmet need for novel and effective therapies. In this context, the transmembrane receptor guanylyl cyclase C (GUCY2C) has emerged as an attractive target for the prevention, detection and treatment of many gastrointestinal tumors. GUCY2C is an intestinally-restricted protein implicated in tumorigenesis that is universally expressed by primary and metastatic colorectal tumors as well as ectopically expressed by esophageal, gastric and pancreatic cancers. This review summarizes the current state of GUCY2C-targeted modalities in the management of gastrointestinal malignancies, with special focus on colorectal cancer, the most incident gastrointestinal malignancy.
- Subjects :
- 0301 basic medicine
Colorectal cancer
medicine.medical_treatment
Clinical Biochemistry
Receptors, Enterotoxin
Context (language use)
Review
03 medical and health sciences
0302 clinical medicine
Drug Discovery
medicine
Humans
Gastrointestinal cancer
Molecular Targeted Therapy
Gastrointestinal Neoplasms
business.industry
Stomach
Biochemistry (medical)
Cancer
Immunotherapy
Guanylate cyclase 2C
medicine.disease
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Cancer research
Pancreas
business
Biomarkers
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Biomark Med
- Accession number :
- edsair.doi.dedup.....0f8cb9a2c879e8667480f935b2f17f6b